Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes.
暂无分享,去创建一个
Martin Möckel | Rainer Dietz | Wolfgang Koenig | Ulrich Frei | A. Jaffe | W. Koenig | R. Dietz | M. Möckel | U. Frei | Allan S Jaffe | Christian Müller | C. Müller | Oliver Danne | Reinhold Müller | Jörn O Vollert | Christian Lueders | Thomas Störk | J. Vollert | T. Störk | O. Danne | R. Müller | C. Lueders
[1] M. Al-Nozha,et al. Haemostatic variables in patients with unstable angina. , 1994, International journal of cardiology.
[2] N. Kleiman,et al. Soluble CD40 ligand in acute coronary syndromes. , 2003, The New England journal of medicine.
[3] A. Hofman,et al. Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study , 2005, Circulation.
[4] M. Hadamitzky,et al. Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.
[5] M. Möckel,et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. , 2003, The American journal of cardiology.
[6] M. Emdin,et al. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natr , 2004, Clinical chemistry and laboratory medicine.
[7] A. Siegbahn,et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.
[8] D. Morrow,et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes☆ , 2002 .
[9] K. Huber,et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. , 2004, Journal of the American College of Cardiology.
[10] C. Heeschen,et al. Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.
[11] K. Lackner,et al. Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room. , 2005, Clinical chemistry.
[12] M. Möckel,et al. Whole-blood hypercholinemia and coronary instability and thrombosis. , 2005, Clinical chemistry.
[13] Leo Breiman,et al. Classification and Regression Trees , 1984 .
[14] L. Wallentin,et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. , 2005, Journal of the American College of Cardiology.
[15] A. Wu,et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. , 2004, Clinical chemistry.
[16] M. Sabatine,et al. Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial , 2006, Circulation.
[17] A. Laggner,et al. Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. , 2002, Clinical chemistry.
[18] F. Apple,et al. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. , 2007, Clinical chemistry.
[19] Prof. Dr. med. C. W. Hamm,et al. Leitlinien: Akutes Koronarsyndrom (ACS) , 2004, Zeitschrift für Kardiologie.
[20] A. Go,et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. , 2001, Journal of the American College of Cardiology.
[21] C. Hamm,et al. [Guidelines: acute coronary syndrome (ACS). 1: ACS without persistent ST segment elevations]. , 2004, Zeitschrift fur Kardiologie.
[22] M. Möckel,et al. Whole blood choline and plasma choline in acute coronary syndromes: prognostic and pathophysiological implications. , 2007, Clinica chimica acta; international journal of clinical chemistry.
[23] G. Lowe,et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.
[24] C. Heeschen,et al. Prognostic value of placental growth factor in patients with acute chest pain. , 2004, JAMA.
[25] TorbjørnOmland,et al. N-Terminal Pro-B–Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002 .
[26] E. Antman,et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. , 2004, Journal of the American College of Cardiology.
[27] Antoni Bayes-Genis,et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.
[28] J. Kruskal,et al. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. , 1987, The New England journal of medicine.
[29] Robert H Christenson,et al. Stratus CS cardiac troponin I method: performance characteristics including imprecision at low concentrations. , 2004, Clinical biochemistry.
[30] R. Califf,et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. , 2005, JAMA.
[31] B. Lindahl,et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. , 2002, Journal of the American College of Cardiology.
[32] J. Manson,et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. , 2001, Journal of the American College of Cardiology.
[33] Nader Rifai,et al. Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.
[34] D. Tschoepe,et al. Angina intensity is not different in diabetic and non-diabetic patients with acute myocardial infarction , 2003, Zeitschrift für Kardiologie.
[35] Fred S Apple,et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. , 2005, Clinical chemistry.
[36] H. Brenner,et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. , 2005, Atherosclerosis.
[37] F. Cambien,et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. , 2003, Journal of lipid research.
[38] C. Heeschen,et al. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. , 2005, Journal of the American College of Cardiology.
[39] C. Heeschen,et al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. , 2006, Journal of the American College of Cardiology.
[40] E. Brilakis,et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. , 2005, European heart journal.
[41] C. Packard,et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease , 2000 .
[42] J S Alpert,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.
[43] Heejung Bang,et al. Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.
[44] J. Hinde,et al. Models for diagnosing chest pain: is CART helpful? , 1997, Statistics in medicine.